Morphic Therapeutic (NASDAQ:MORPH), a US clinical-stage biotech developing oral drugs for autoimmune/ chronic inflammation disorders, was acquired by Eli Lilly earlier this month for US$3.2bn.
Successful Phase 2a results for the company’s lead drug in the indication of ulcerative colitis were announced in April last year. The Phase 2b trial of the same drug in ulcerative colitis and another in a Phase 2b study in Crohn’s disease are expected to complete in approximately 12 months. The company also has four other molecules in pre-clinical.
While Morphic is neither a neurology nor rare disease-focused company, how the deal played out, as outlined in a subsequent SEC filing SEC filing, may be of interest.
https://investor.morphictx.com/node/9746/html
Morphic Therapeutic (NASDAQ:MORPH), a US clinical-stage biotech...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.52 |
Change
0.310(2.04%) |
Mkt cap ! $1.983B | |||
| Open | High | Low | Value | Volume |
| $15.19 | $15.62 | $15.11 | $8.655M | 558.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 440 | $15.48 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.54 | 752 | 1 |
View Market Depth
| Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |